Key result
Dantrolene administration effectively treated Miyoshi myopathy in two siblings with a novel compound heterozygous dysferlin mutation, evidenced by decreased serum creatine kinase levels.
Why the study?
Does dantrolene improve serum creatine kinase levels in patients with Miyoshi myopathy?
Case Report (n=2)
Does dantrolene improve serum creatine kinase levels in patients with Miyoshi myopathy?
Dantrolene may be an effective treatment for lowering serum creatine kinase in patients with Miyoshi myopathy harboring dysferlin mutations.
No takes yet. Share an insight, caveat, or question.
May lower CK in dysferlin Miyoshi myopathy; hypothesis-generating and requires controlled trials before any practice change.
Hattori et al. (2007) conducted a case report in Miyoshi myopathy (n=2). Dantrolene was evaluated on Serum creatine kinase (CK) levels. Dantrolene administration effectively treated Miyoshi myopathy in two siblings with a novel compound heterozygous dysferlin mutation, evidenced by decreased serum creatine kinase levels.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: